A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

NCT ID: NCT03793686

Last Updated: 2020-10-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-06
• Study Completion Date: 2020-09-01

Brief Summary

This Phase I double blind, randomized clinical study to evaluate the safety of human milk oligosaccharides (HMO) is designed to assess the safety and dosage ranging of PBCLN-003 in adults with Clostridium difficile-associated diarrhea (CDAD). Within 3 dose cohort, subjects will be randomized in a 3:1 ratio to receive PBCLN-003 or placebo.

Conditions

Clostridium Difficile Diarrhea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Experimental

PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts

Group Type: EXPERIMENTAL

PBCLN-003

Intervention Type: DRUG

Investigational drug

Placebo

Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

PBCLN-003

Investigational drug

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Enrollment episode of CDAD diagnosed based on > 3 loose stools per day and detection of CD toxin by nucleic acid amplification tests (NAAT), EIA or GDH
• Mild to moderate CDAD during enrollment episode (per Society of Hospital Epidemiologists of America (SHEA)/lnfectious Disease Society of America(ISDA) criteria)
• Current therapy with standard of care antibiotics for recurrent CDAD(vancomycin, metronidazole, fidaxomicin)
• BMI > 18.5 and < 40
• Age 18 years or older
• Agreement to adhere to the study protocol
• Informed consent is obtained
• Women who are capable of bearing children must have a negative pregnancy test at the time of screening
• Female subjects of childbearing potential must use birth control (defined as oral or injectable contraceptives, intrauterine devices, surgical sterilization or a combination of a condom and spermicide) during the study period and for up to 8 weeks after the first drug of study.

Exclusion Criteria

• Severe CDAD during enrollment episode (per SHEA/ISDA criteria) characterized as follows:

• History of five (5) or more recurrences of CDAD within the past 12 months prior to potential study enrollment
• History of fecal microbiome transplant or other microbiome directed experimental intervention for CDAD
• History (ever) of CD complicating inflammatory bowel disease (Crohn's disease, ulcerative colitis), or history of bowel resection surgery (other than uncomplicated appendectomy) or history of other infectious diarrhea or diarrhea of unknown etiology since the initial episode of CDAD
• Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
• Initiating a new diet or weight loss amounting to 10% within two weeks prior to date of study entry
• Enrolled in another clinical study for the therapy of CDAD or affecting nutritional management during the study period
• Enrolled or has been enrolled in another experimental (IND) study within two weeks prior to date of study entry
• Is pregnant or lactating
• History of swallowing difficulties, including dysphagia or odynophagia for liquids or solids
• Use of any Probiotics (any formulation) within the two weeks prior to date of study entry
• New, or a change in the consumption of the following prescription medications or over-the-counter (OTC) medications within two weeks prior to date of study entry:

• Proton pump inhibitors (for example: Prilosec®, Nexium®)
• Histamine-2 receptor antagonists (for example: Zantac®, Pepcid®)
• Consumption of the following prescription medications during the current enrollment episode: • Bezlotuxamab/Zinplava®

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Prolacta Bioscience

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David J Rechtman, MD

Role: STUDY_DIRECTOR

Vice President, Medical Affairs, Prolacta Bioscience

Locations

Infectious Disease Specialist

Idaho Falls, Idaho, United States

Countries

United States

Other Identifiers

18-CT-001

Identifier Type: -

Identifier Source: org_study_id